Ursodeoxycholic acid combined with bezafibrate in the treatment of refractory primary biliary cholangitis: a meta-analysis
10.3760/cma.j.issn.1007-3418.2019.04.012
- VernacularTitle: 熊去氧胆酸联合苯扎贝特治疗难治性原发性胆汁性胆管炎的Meta分析
- Author:
Bailei FENG
1
;
Huihong YU
;
Wei SHEN
Author Information
1. The Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
- Publication Type:Journal Article
- Keywords:
Bezafibrate;
Liver cirrhosis, biliary;
Deoxycholic acid;
Meta-analysis
- From:
Chinese Journal of Hepatology
2019;27(4):304-311
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy, safety and remission rates of pruritus of bezafibrate and UDCA combination therapy in the treatment of refractory PBC.
Methods:PubMed, Embase, The Cochrane Library databases, Science direct, Web of Science, CBM, WangFang Data, CNKI, VIP databases were searched to collect randomized controlled trials, crossover trials and self-control clinical trials of combination therapy of UDCA and bezafibrate with UDCA monotherapy for PBC up to June, 2018. RevMan 5.3 software was used for meta-analysis. Two evaluators independently screened the literature, extracted the data, and evaluated the risk of bias of relevant study.
Results:Eleven studies, including 465 patients were included. Ursodeoxycholic acid combined with bezafibrate had greatly improved liver biochemical indicators (P < 0.01) and pruritus scores in patients with refractory primary biliary cholangitis (MD = -2.97, 95% CI: -4.34~ -1.60, P < 0.01). However, there was no statistically significant differences in adverse events (RR = 1.28, 95% CI: 0.96 to 1.70, P = 0.09), and mortality rate (RR = 2.58, 95% CI: 0.57 to 11.73, P = 0.22) between the two groups.
Conclusion:Ursodeoxycholic acid combined with bezafibrate may improve the biochemical response and pruritus score of refractory PBC, but has no significant effect on adverse events and mortality rate.
